Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

Last year, pharmaceutical ... $1 billion less than AbbVie's acquisition of Cerevel. Still, the company survived the Rova-T ...

Biotech companies can be volatile, but have the potential to continue expanding their product portfolio and boost their ...

As of Q3 2024, Humira sales were $2.2 billion globally, but AbbVie's total revenue was $14.4 billion. Its immunology portfolio (which includes all three of the medicines) grew by 3.9% year over ...